Citigroup’s Bio-Techne TECH Stock Holding History

Citigroup’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-79,500	Closed	-$6.35M	–	5958
2024 Q3	$6.35M	Buy	79,500 +41,700	+110%	+$3.13M	﹤0.01%	1653
2024 Q2	$2.71M	Sell	37,800 -19,200	-34%	-$1.41M	﹤0.01%	2095
2024 Q1	$4.01M	Buy	+57,000	New	+$4.08M	﹤0.01%	1880

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Citigroup's TECH Position: Q2 2026 in Review

Citigroup increased its Bio-Techne (TECH) stake by 106% in Q2 2026, buying an estimated $12.4M and bringing the position to 445,145 shares worth $31.4M. The position accounts for 0.01% of the portfolio, ranked #941.

Citigroup first reported a position in TECH in Q2 2013 and has held it in 53 quarters since. 595 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Citigroup held 445,145 shares of Bio-Techne worth $31.4M as of Q2 2026.
Citigroup bought 229,185 Bio-Techne shares in Q2 2026, an estimated $12.4M.
Bio-Techne made up 0.01% of Citigroup's portfolio in Q2 2026, its #941 holding.
Citigroup first reported a position in Bio-Techne in Q2 2013 and has held it in 53 quarters since.
595 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.